IRIS Accounts Production v25.1.3.33 13877031 director 1.2.24 31.1.25 31.1.25 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh138770312024-01-31138770312025-01-31138770312024-02-012025-01-31138770312023-01-31138770312023-02-012024-01-31138770312024-01-3113877031ns15:EnglandWales2024-02-012025-01-3113877031ns14:PoundSterling2024-02-012025-01-3113877031ns10:Director12024-02-012025-01-3113877031ns10:PrivateLimitedCompanyLtd2024-02-012025-01-3113877031ns10:SmallEntities2024-02-012025-01-3113877031ns10:AuditExempt-NoAccountantsReport2024-02-012025-01-3113877031ns10:SmallCompaniesRegimeForDirectorsReport2024-02-012025-01-3113877031ns10:SmallCompaniesRegimeForAccounts2024-02-012025-01-3113877031ns10:FullAccounts2024-02-012025-01-3113877031ns10:RegisteredOffice2024-02-012025-01-3113877031ns5:CurrentFinancialInstruments2025-01-3113877031ns5:CurrentFinancialInstruments2024-01-3113877031ns5:ShareCapital2025-01-3113877031ns5:ShareCapital2024-01-3113877031ns5:RetainedEarningsAccumulatedLosses2025-01-3113877031ns5:RetainedEarningsAccumulatedLosses2024-01-3113877031ns5:PlantMachinery2024-01-3113877031ns5:PlantMachinery2024-02-012025-01-3113877031ns5:PlantMachinery2025-01-3113877031ns5:PlantMachinery2024-01-3113877031ns5:WithinOneYearns5:CurrentFinancialInstruments2025-01-3113877031ns5:WithinOneYearns5:CurrentFinancialInstruments2024-01-3113877031ns5:Non-currentFinancialInstrumentsns5:AfterOneYear2025-01-3113877031ns5:Non-currentFinancialInstrumentsns5:AfterOneYear2024-01-31
REGISTERED NUMBER: 13877031 (England and Wales)















Unaudited Financial Statements for the Year Ended 31 January 2025

for

Oak Pharma Ltd

Oak Pharma Ltd (Registered number: 13877031)

Contents of the Financial Statements
for the Year Ended 31 January 2025










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Oak Pharma Ltd

Company Information
for the Year Ended 31 January 2025







DIRECTOR: C S Uppal





REGISTERED OFFICE: 52 Bell Road
Walsall
WS5 3JW





REGISTERED NUMBER: 13877031 (England and Wales)






Oak Pharma Ltd (Registered number: 13877031)

Balance Sheet
31 January 2025

31.1.25 31.1.24
Notes £    £   
FIXED ASSETS
Tangible assets 4 601 902

CURRENT ASSETS
Debtors 5 10,665 16,888
Cash at bank and in hand 107,208 63,048
117,873 79,936
CREDITORS
Amounts falling due within one year 6 (116,873 ) (74,802 )
NET CURRENT ASSETS 1,000 5,134
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,601

6,036

CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings 1,501 5,936
1,601 6,036

Oak Pharma Ltd (Registered number: 13877031)

Balance Sheet - continued
31 January 2025


The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 January 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 January 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 16 May 2025 and were signed by:





C S Uppal - Director


Oak Pharma Ltd (Registered number: 13877031)

Notes to the Financial Statements
for the Year Ended 31 January 2025


1. STATUTORY INFORMATION

Oak Pharma Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Computer Equipment 20% Reducing Balance

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Oak Pharma Ltd (Registered number: 13877031)

Notes to the Financial Statements - continued
for the Year Ended 31 January 2025


2. ACCOUNTING POLICIES - continued

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2024 - 1 ) .

4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 February 2024
and 31 January 2025 902
DEPRECIATION
Charge for year 301
At 31 January 2025 301
NET BOOK VALUE
At 31 January 2025 601
At 31 January 2024 902

5. DEBTORS
31.1.25 31.1.24
£    £   
Amounts falling due within one year:
Trade debtors 10,665 17,488

Amounts falling due after more than one year:
Other debtors - (600 )

Aggregate amounts 10,665 16,888

Oak Pharma Ltd (Registered number: 13877031)

Notes to the Financial Statements - continued
for the Year Ended 31 January 2025


6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.1.25 31.1.24
£    £   
Taxation and social security 7,790 8,525
Other creditors 109,083 66,277
116,873 74,802